Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Defibrotide (Defitelio®) is recommended for use within NHS Wales for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | defibrotide (Defitelio®) | ||
| Formulation | 80 mg/ml concentrate for solution for infusion | ||
| Reference number | 508 | ||
| Indication | Treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy in adults, adolescents, children and infants over one month of age |
||
| Company | Jazz Pharmaceuticals plc | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0515 | ||
| NMG meeting date | 25/02/2015 | ||
| AWMSG meeting date | 25/03/2015 | ||
| Ratification by Welsh Government | 15/05/2015 | ||
| Date of issue | 20/05/2015 | ||
| Date of last review | 27/03/2018 | ||
| Commercial arrangement | WPAS | ||